Quest PharmaTech Inc. Fundamental Analysis
Quest PharmaTech Inc. (QPTFF) shows moderate financial fundamentals with a PE ratio of 1.54, profit margin of 0.00%, and ROE of 21.70%. The company generates N/A in annual revenue with weak year-over-year growth of 0.00%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 39.7/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze QPTFF's fundamental strength across five key dimensions:
Efficiency Score
ExcellentQPTFF demonstrates superior asset utilization.
Valuation Score
ExcellentQPTFF trades at attractive valuation levels.
Growth Score
ModerateQPTFF shows steady but slowing expansion.
Financial Health Score
ModerateQPTFF shows balanced financial health with some risks.
Profitability Score
ModerateQPTFF maintains healthy but balanced margins.
Key Financial Metrics
Is QPTFF Expensive or Cheap?
P/E Ratio
QPTFF trades at 1.54 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, QPTFF's PEG of -0.00 indicates potential undervaluation.
Price to Book
The market values Quest PharmaTech Inc. at 0.28 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 14.34 times EBITDA. This signals the market has high growth expectations.
How Well Does QPTFF Make Money?
Net Profit Margin
For every $100 in sales, Quest PharmaTech Inc. keeps $0.00 as profit after all expenses.
Operating Margin
Core operations generate 0.00 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $21.70 in profit for every $100 of shareholder equity.
ROA
Quest PharmaTech Inc. generates $17.06 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
FCF Per Share
Each share generates $0.00 in free cash annually.
FCF Yield
QPTFF converts 0.47% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
1.54
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-0.00
vs 25 benchmark
P/B Ratio
Price to book value ratio
0.28
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.00
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.04
vs 25 benchmark
Current Ratio
Current assets to current liabilities
0.02
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.22
vs 25 benchmark
ROA
Return on assets percentage
0.17
vs 25 benchmark
ROCE
Return on capital employed
-0.02
vs 25 benchmark
How QPTFF Stacks Against Its Sector Peers
| Metric | QPTFF Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 1.54 | 29.17 | Better (Cheaper) |
| ROE | 21.70% | 726.00% | Weak |
| Net Margin | 0.00% | -51411.00% (disorted) | Weak |
| Debt/Equity | 0.04 | 0.49 | Strong (Low Leverage) |
| Current Ratio | 0.02 | 4.40 | Weak Liquidity |
| ROA | 17.06% | -21859.00% (disorted) | Strong |
QPTFF outperforms its industry in 3 out of 6 key metrics, particularly excelling in ROA, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Quest PharmaTech Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
0.00%
Industry Style: Defensive, Growth, Innovation
DecliningEPS CAGR
70.16%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
91.81%
Industry Style: Defensive, Growth, Innovation
High Growth